CNS Pharmaceuticals to Present at Two Investor Conferences in April
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Brain
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical...
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4...
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront...
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The...
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from...
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development...
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
Data Published in Leading Peer-Reviewed Publication, Journal of Clinical MedicineJERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay...
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
TORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased...
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
IntraBio Announces U.S. FDA Accepts New Drug Application for IB1001 for the Treatment of Niemann-Pick Disease Type C
IntraBio's IB1001 New Drug Application was accepted and granted priority reviewPDUFA date set for September 24th, 2024Application based on positive...
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi...
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma...
Congress Passes Bills Making Major Investments in Alzheimer’s
Bill Increases Funding for Alzheimer’s Research and Prevention EffortsWASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget...
Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that its Board...
IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam
GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company...
Precision Neuroscience Expands Clinical Research In Brain–Computer Interface
New studies at Mount Sinai Health System and Penn Medicine investigate how the brain controls movementNEW YORK, March 22, 2024...
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a...
Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain
World’s first legal exporters of psilocybin solidifies partnership with acclaimed university in Canada for preclinical studiesRUNAWAY BAY, Jamaica, March 21,...